Submitted by Anonymous (not verified) on 14 September 2026 - 14:54
Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 8, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 8, Status: Authorised